{"id":"ff82e5a0-8955-41ed-a713-2a8984df979f","modelId":"1ede4325-d956-495d-b01b-3e5ffad096a9","versionId":null,"locationId":"404b0287-1c78-47b0-b802-f57cbcac872a","operatorId":null,"ownerId":null,"slug":"histosonics-edison-cleveland-ohio-usa","status":"operational","firstSeen":"2023-12-01T00:00:00.000Z","statusChangeReason":null,"contractType":null,"pilotOutcome":null,"endedAt":null,"unitsOnSite":null,"tasksPerformed":null,"shiftStructure":null,"hoursPerDay":null,"siteType":null,"operatorConfirmed":null,"humanSupervisionOnsite":null,"locationPrecisionTier":null,"deploymentScale":null,"siteEnvironment":null,"operatorType":null,"sourceQualityTier":null,"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://histosonics.com/worlds-first-patients-treated-with-novel-edison-histotripsy-system/","name":"HistoSonics","title":"World's First Patients Treated With Novel Edison® Histotripsy System"}],"notes":"Cleveland Clinic treated initial patients suffering from liver tumors using the Edison histotripsy system in the same week as URMC's first treatment (December 2023). Led by Dr. C.H. David Kwon. Three patients treated initially.","keyFacts":[],"reviewNote":null,"exposureHours":null,"deploymentMilesEstimate":null,"exposureBasis":null,"customerSegment":null,"scaleTier":null,"contractValueUsd":null,"contractValueBasis":null,"customerCompanyId":null,"customerExternalName":null,"createdAt":"2026-08-08T22:32:58.082Z","updatedAt":"2026-08-09T04:18:52.239Z","model":{"id":"1ede4325-d956-495d-b01b-3e5ffad096a9","companyId":"fffa2127-5d46-4965-b510-cf96161154f0","modelName":"Edison Histotripsy System","slug":"histosonics-edison","description":"Robotic, image-guided focused ultrasound (histotripsy) platform that mechanically destroys and liquefies targeted tumors non-invasively without incisions. Uses a robotic arm to deliver focused ultrasound energy. First and only histotripsy platform cleared for clinical use globally.","formFactor":"surgical","industryVertical":null,"environment":null,"maturityStage":"commercial","lifecycleState":"active","supersededByModelId":null,"specs":{},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://histosonics.com/","title":"HistoSonics | Leader in Histotripsy","sourceName":"HistoSonics"},{"url":"https://www.massdevice.com/histosonics-edison-histotripsy-fda-kidney-tumors/","title":"HistoSonics submits Edison histotripsy tech to FDA for kidney tumors","sourceName":"MassDevice"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"keyFacts":[{"label":"FDA clearance","value":"De Novo 2023 (liver tumors)"},{"label":"Type","value":"Robotic histotripsy / focused ultrasound"},{"label":"Maturity","value":"Commercial / FDA-cleared"},{"label":"Applications","value":"Liver tumors (cleared), kidney (pending), pancreatic (planned)"}],"createdAt":"2026-07-23T13:40:39.557Z","updatedAt":"2026-08-09T03:57:34.330Z","unitsInFieldClaimed":null,"unitsInFieldVerified":null,"unitsManufacturedClaimed":null,"unitsManufacturedVerified":null,"unitsAsOf":null,"unitsSource":null,"salesModel":null,"priceUndisclosedSince":null,"autonomyClass":"supervised","autonomyStatement":null,"autonomyStatementSource":null,"demoForensics":null,"exportControlClass":null,"minCommitment":null,"warrantyTerms":null,"serviceModel":null,"productionRateClaimed":null,"productionRateEvidenced":null,"teleopRatioDisclosed":null,"interventionRateDisclosed":null,"company":{"id":"fffa2127-5d46-4965-b510-cf96161154f0","name":"HistoSonics","slug":"histosonics","description":"Plymouth, Minnesota-based medical device company developing the Edison Histotripsy System — a robotically assisted platform using focused ultrasound to non-invasively destroy liver tumors. FDA De Novo clearance October 2023. Raised $102M Series D led by Alpha Wave Ventures, valued at $3.75B. Expanding to kidney, pancreas, prostate applications.","status":null,"founded":2009,"hq":"Plymouth, MN, USA","hqLat":45.0065149,"hqLng":-93.46651,"hqGeocodedAt":"2026-08-05T14:32:55.061Z","hqAddress":null,"hqPrecision":null,"website":"histosonics.com","fundingTotal":null,"type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://histosonics.com/","title":"HistoSonics | Leader in Histotripsy","sourceName":"HistoSonics"},{"url":"https://www.massdevice.com/histosonics-edison-histotripsy-fda-kidney-tumors/","title":"HistoSonics submits Edison histotripsy tech to FDA for kidney tumors","sourceName":"MassDevice"},{"url":"https://histosonics.com/histosonics-secures-102m-series-d-financing/","title":"HistoSonics Secures $102M Series D Financing","sourceName":"HistoSonics"},{"url":"https://www.massdevice.com/histosonics-stake-acquired-2b-investor-syndicate/","title":"HistoSonics stake acquired by $2B investor syndicate","sourceName":"MassDevice"}],"keyFacts":[{"label":"Funding","value":"$102M Series D + $2B+ acquisition"},{"label":"CEO","value":"Mike Blue"},{"label":"Form factor","value":"Surgical (histotripsy / focused ultrasound)"},{"label":"FDA status","value":"De Novo authorized 2023 (liver); kidney pending"},{"label":"CE Mark","value":"July 2026"},{"label":"Founded","value":"2009"},{"label":"Stage","value":"Commercial (FDA-cleared)"},{"label":"Product","value":"Edison Histotripsy System (FDA De Novo cleared Oct 2023)"},{"label":"Total funding","value":"$102M+ Series D (Alpha Wave Ventures led)"},{"label":"Valuation","value":"$3.75B (2026)"},{"label":"FDA pathway","value":"De Novo clearance for liver tumor destruction"},{"label":"Investors","value":"Alpha Wave Ventures, Amzak Health, HealthQuest Capital, J&J Innovation"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-07-23T13:40:08.115Z","updatedAt":"2026-08-05T14:42:47.047Z"}},"version":null,"location":{"id":"404b0287-1c78-47b0-b802-f57cbcac872a","name":"Cleveland Clinic","slug":"cleveland-ohio-usa","kind":"hospital","parentLocationId":null,"region":null,"lat":null,"lng":null,"reviewStatus":"reviewed","aliases":[],"collisionRisk":"high","reviewNote":null,"createdAt":"2026-08-08T22:32:50.209Z","updatedAt":"2026-08-09T04:26:19.821Z"},"operator":null,"owner":null,"derived":{"trustTier":"unverified","currentPosture":null},"jsonLd":{"@context":"https://schema.org","@type":"Event","@id":"https://registry.deploy.report/deployments/histosonics-edison-cleveland-ohio-usa","url":"https://registry.deploy.report/deployments/histosonics-edison-cleveland-ohio-usa","name":"Edison Histotripsy System at Cleveland Clinic","identifier":"ff82e5a0-8955-41ed-a713-2a8984df979f","startDate":"2023-12-01T00:00:00.000Z","location":{"@type":"Place","@id":"https://registry.deploy.report/locations/cleveland-ohio-usa","name":"Cleveland Clinic"},"organizer":{"@type":"Organization","@id":"https://registry.deploy.report/companies/histosonics","name":"HistoSonics"},"about":{"@type":"Product","@id":"https://registry.deploy.report/models/histosonics-edison","name":"Edison Histotripsy System"},"publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":"commercial","lifecycle_state":"active","architectural_position":{"cohort":"surgical","sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}